The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-05

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

NCT05695417

Non-proliferative Diabetic Retinopathy

ACTIVE_NOT_RECRUITING PHASE1

A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens

NCT01061268

Dry Eye

COMPLETED PHASE4

Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT00403715

Dry Eye Disease

COMPLETED PHASE3

Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

NCT05467293

Dry Eye

COMPLETED PHASE2

A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye

NCT05201170

Dry Eye Dry Eye Syndromes

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1.0 RATIONALE AND NEEDS ASSESSMENT Primary Eyepoint Drug(s): YUTIQ

Study Rationale:

The current data shows that in eyes from patients with chronic non-infectious posterior uveitis(NIPU), a single YUTIQ implant decreases the number of uveitis recurrences, led to less necessary adjunctive treatments, demonstrated less visual acuity loss, and had an acceptable side effect profile. Naturally, we asked whether two YUTIQ implants at the time of treatment would lead to an improved level of control of intraocular inflammation. We propose to evaluate the safety and efficacy of two YUTIQ implants versus two sham injections to manage inflammation associated with NIPU.

Needs Assessment:

Chronic noninfectious uveitis of the posterior segment of the eye is a visually debilitating disease to patients affected with it. Untreated or undertreated recurrent episodes of inflammation in these patients lead to permanent damage to the intraocular structures of the eye resulting in irreversible vision loss. Recent data has shown that a single YUTIQ implant demonstrated an improved level of control of intraocular inflammation, decreased frequency of uveitis flare ups, and led to less visual acuity loss compared to sham. However, there were still patients in the treatment group who had suboptimal control of their intraocular inflammation, experienced uveitis flares, and had a decrease in best-corrected visual acuity (BCVA). A study evaluating two YUTIQ implants for chronic NIPU would provide data to address whether this treatment paradigm would lead to superior outcomes and reduced treatment burden. There are currently no published prospective trials that have evaluated primary therapy with two YUTIQ implants.

In this study, we aim to compare the recurrence rate of uveitis by month 6 of two YUTIQ intravitreal implants to sha m. The clinical definition of intraocular inflammation recurrence is ( a 2 step or more increase in number of cells in the anterior chamber per high powered field (x1.6 using a 1 mm beam), ( a 2 step or more increase in vitreous haze, or ( a deterioration in BCVA of 15 letters or more. We expect a decreased rate of uveitis recurrences compared to sham. We also expect a decrease in inflammatory recurrences and increased time to first recurrence compared to prior data evaluating the use of a single YUTI Q implant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uveitis Uveitis, Posterior Uveitis, Anterior Uveitis, Intermediate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

1 year, prospective, randomized, collaborative study.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

The subject and the examining doctor will be masked to the treatment the subject receives on day 1.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Arm

This group will receive two YUTIQ implants at day 1.

Group Type EXPERIMENTAL

Yutiq 0.18 MG Drug Implant

Intervention Type DRUG

YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection

Control Arm

This group will receive two sham injections at day 1.

Group Type SHAM_COMPARATOR

Sham Injection

Intervention Type OTHER

Sham injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Yutiq 0.18 MG Drug Implant

YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection

Intervention Type DRUG

Sham Injection

Sham injection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or non-pregnant female in good general health at least 18 years of age, understands the language of the informed consent, and is willing and able to provide written informed consent and sign/date a health information release (HIPAA form) before any study procedures are performed.
2. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

1. Diagnosed with chronic unilateral or bilateral noninfectious posterior segment inflammation (with or without anterior uveitis) that demonstrated a clinical response to ≥1 previous corticosteroid treatment of any localized type (eg, topical steroid 2 to 4 times per day or intra- or peri-ocular injection) or systemic corticosteroid/immunosuppressant treatment with recurrence following treatment indicating chronicity according to the Investigator's judgment.
2. Presence of active posterior segment inflammation as determined by the Investigator.
3. Vitreous haze grade ≥ 2 based on the standardization of uveitis nomenclature (SUN) criteria.
4. Less than 10 anterior chamber cells/high power field determined by slit lamp examination.
5. Not planning to undergo elective ocular surgery during the study.

Exclusion Criteria

1. Subjects with known hypersensitivity to any components of YUTIQ.
2. Female subjects who are pregnant or breastfeeding.
3. Has any acute or chronic medical disease or psychiatric condition that, in the opinion of the Investigator, would preclude participation in the study or put the subject at risk due to study treatment or procedures.

1. History of anterior uveitis only (without associated uveitis that affected the posterior segment).
2. Presence of a vitreous hemorrhage.
3. Uveitis with infectious etiology.
4. Intraocular inflammation associated with a condition other than non-infectious uveitis (e.g., intraocular lymphoma).
5. Current infectious diseases of the cornea and conjunctiva, mycobacterial infections of the eye, or fungal diseases of ocular structures.
6. Subjects with ACIOL (Anterior Chamber Intraocular Lens) or rupture of the posterior lens capsule.
7. Diagnosis of any form of glaucoma or ocular hypertension at screening, unless the study eye is being treated with ≤2 intraocular pressure (IOP)-lowering medications and/or has been previously treated with an incisional surgical procedure resulting in stable IOP in the normal range (10 to 21 mmHg).
8. Intraocular pressure \>21 mmHg or concurrent therapy at screening with \>2 IOP-lowering pharmacologic agents in the study eye.
9. Any eye surgery within 12 weeks prior to Day 1 of the study.
10. Subjects who are unable to attend scheduled follow-up visits throughout the 12-month study.
11. Has a significant media opacity precluding evaluation of retina and vitreous in the study eye.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No